The influence of the Pharmaceutical Benefits Scheme (PBS) on inappropriate prescribing in Australian nursing homes

ISSN： 0928-1231

Source： Pharmacy World and Science, Vol.29, Iss.1, 2007-02, pp. : 39-42

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clopidogrel Prescribing and Concordance with the Pharmaceutical Benefits Scheme in Hospital Patients

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 39, Iss. 4, 2009-12 ,pp. : 265-268

John Wiley & Sons Inc

Access to resources Recommend Favorite

Administrative Initiatives for Reducing Inappropriate Prescribing of Psychotropic Drugs in Nursing Homes: How Successful Have They Been?

By Hughes Carmel M.

Drugs & Aging, Vol. 22, Iss. 4, 2005-01 ,pp. : 339-351

Adis International

Access to resources Recommend Favorite

Potentially Inappropriate Prescribing in Older People with Dementia in Care Homes: A Retrospective Analysis

By Parsons Carole

Drugs & Aging, Vol. 29, Iss. 2, 2012-02 ,pp. : 143-155

Adis International

Access to resources Recommend Favorite

The Use of QALY Weights for QALY Calculations: A Review of Industry Submissions Requesting Listing on the Australian Pharmaceutical Benefits Scheme 2002-4

By Scuffham Paul A.

PharmacoEconomics, Vol. 26, Iss. 4, 2008-01 ,pp. : 297-310

Adis International

Access to resources Recommend Favorite

The federal government in Australia has announced that Pfizer's atorvastatin [Lipitor] warrants a higher price than Merck & Co's simvastatin [Zocor] for Pharmaceutical Benefits Scheme (PBS) subsidy

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 483, 2005-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite